Statistiche di base
| CIK | 1785345 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Landos Biopharma, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-39971 LANDOS BIOPHARMA, INC. (Exact name of registrant as specified in i |
|
| May 23, 2024 |
As filed with the Securities and Exchange Commission on May 23, 2024 As filed with the Securities and Exchange Commission on May 23, 2024 Registration No. |
|
| May 23, 2024 |
As filed with the Securities and Exchange Commission on May 23, 2024 As filed with the Securities and Exchange Commission on May 23, 2024 Registration No. |
|
| May 23, 2024 |
FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION LANDOS BIOPHARMA, INC. Exhibit 3.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LANDOS BIOPHARMA, INC. FIRST: The name of the corporation is Landos BioPharma, Inc. (hereinafter, the “Corporation”). SECOND: The address of the Corporation’s registered office in the State of Delaware is c/o Corporate Creations Network Inc., 1521 Concord Pike Suite 201, Wilmington, DE 19803, New Castle County, USA, and the nam |
|
| May 23, 2024 |
Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 23, 2024 |
As filed with the Securities and Exchange Commission on May 23, 2024 As filed with the Securities and Exchange Commission on May 23, 2024 Registration No. |
|
| May 23, 2024 |
As filed with the Securities and Exchange Commission on May 23, 2024 As filed with the Securities and Exchange Commission on May 23, 2024 Registration No. |
|
| May 23, 2024 |
### Media: Lindsay Cangemi [email protected] Investors: Liz Shea [email protected] Exhibit 99.1 PRESS RELEASE AbbVie Completes Acquisition of Landos Biopharma - Adds first-in-class investigational asset, NX-13, to AbbVie’s pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn’s disease (CD) NORTH CHICAGO, Ill., May 23, 2024 – AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Landos Biopharma, Inc. ( |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 23, 2024 |
LANDOS BIOPHARMA, INC. AMENDED AND RESTATED BYLAWS DATED AS OF MAY 23, 2024 ARTICLE I Exhibit 3.2 LANDOS BIOPHARMA, INC. AMENDED AND RESTATED BYLAWS DATED AS OF MAY 23, 2024 ARTICLE I STOCKHOLDERS Section 1. Annual Meeting. An annual meeting of the stockholders, for the election of the directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, and at such time as th |
|
| May 23, 2024 |
Landos Biopharma, Inc. P.O. Box 11239 Blacksburg, VA 24062 Landos Biopharma, Inc. P.O. Box 11239 Blacksburg, VA 24062 May 23, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 RE: Landos Biopharma, Inc. Withdrawal of Registration Statement on Form S-3 File No. 333-263836 Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the “Se |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39971 Landos Biopharma, Inc. |
|
| April 25, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De |
|
| April 16, 2024 |
Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A (Amendment No. |
|
| April 15, 2024 |
EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Landos Biopharma, Inc. |
|
| April 15, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De |
|
| April 10, 2024 |
LABP / Landos Biopharma, Inc. / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A 1 d770327dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Landos Biopharma, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 515069201 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-534 |
|
| April 10, 2024 |
LABP / Landos Biopharma, Inc. / Xontogeny, LLC - SC 13D/A Activist Investment SC 13D/A 1 d773582dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Landos Biopharma, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 515069201 (CUSIP Number) Christopher Garabedian Xontogeny, LLC 361 Newbury Street, Suite 501 Boston, MA 02115 (857) 891-0017 ( |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pr |
|
| March 25, 2024 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among: BESPIN SUBSIDIARY, LLC, BESPIN MERGER SUB, INC., LANDOS BIOPHARMA, INC., and ABBVIE INC., solely for the limited purposes set forth herein. Dated as of March 24, 2024 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 Section 1.1 The Merger 2 Section 1.2 Closing 2 Section 1.3 Effective Time 2 Section 1.4 Effects of the Merger 2 Section 1.5 Organizational |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pr |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2024 Landos Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39971 81-5085535 (State or other jurisdiction of incorporation) (Commission F |
|
| March 25, 2024 |
Exhibit 99.1 PRESS RELEASE AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases – Landos’ lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC) NORTH CHICAGO, Ill. and NEW YORK, N.Y. March 25, 2024 – AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“ |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2024 Landos Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39971 81-5085535 (State or other jurisdiction of incorporation) (Commission F |
|
| March 25, 2024 |
Exhibit 10.1 VOTING AGREEMENT This VOTING AGREEMENT (this “Agreement”) is being executed and delivered as of March 24, 2024 by and among Xontogeny, LLC, a Delaware limited liability company (together with its Affiliates, including those set forth on Schedule A, “Xontogeny”), Perceptive Advisors LLC, a Delaware limited liability company (together with its Affiliates, including those set forth on Sc |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 21, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Registration Statement on Form S-8 LANDOS BIOPHARMA, INC. |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39971 Landos Biopharma, Inc. |
|
| March 21, 2024 |
Exhibit 99.1 Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results Top-line Results from the NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into mid-2025 NEW YORK, March 21, 2024 –– Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or “the Company”), a clinical-stage biopharmaceutic |
|
| March 21, 2024 |
Landos Biopharma, Inc. Incentive Compensation Recoupment Policy Exhibit 97.1 Landos Biopharma, Inc. Incentive Compensation Recoupment Policy 1. Introduction The Board of Directors (the “Board”) of Landos Biopharma, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment of Recove |
|
| March 21, 2024 |
As filed with the Securities and Exchange Commission on March 21, 2024 As filed with the Securities and Exchange Commission on March 21, 2024 Registration Statement No. |
|
| February 14, 2024 |
LABP / Landos Biopharma, Inc. / Bassaganya-Riera Josep Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Landos Biopharma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 515069102 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| January 4, 2024 |
January 2024 Clinical stage biopharmaceutical company focused on developing first-in-class, oral therapeutics for autoimmune disease Corporate Overview Exhibit 99. |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 04, 2024 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 21, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2023 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 21, 2023 |
Exhibit 99.1 Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn’s and Colitis NX-13, a Novel, Oral, NLRX1 Agonist, was Observed to be Well Tolerated and Demonstrated Early Signs of Rapid Symptomatic Relief and Endoscopic Improvement in Patients with Ulcerative Colitis NEXUS Phase 2 Proof-of-Concept Study is Ongoing, with Top-Line Readout Expected i |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39971 Landos Biopharma, Inc. |
|
| November 9, 2023 |
Exhibit 99.1 Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Remains On Track with Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, November 9, 2023 –– Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developi |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2023 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| September 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 18, 2023 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| September 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2023 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| September 14, 2023 |
Exhibit 99.1 Landos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial Cells Collaboration Will Focus on Defining the Effects Of NX-13 in Ulcerative Colitis Patient Derived Organoid Models NEW YORK, September 14, 2023 –– Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutic |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39971 Landos Biopharma, Inc. |
|
| August 9, 2023 |
Exhibit 99.1 Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results Initiated NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis NEXUS Remains On Track With Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, August 9, 2023 –– Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical co |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 09, 2023 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 30, 2023 |
Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D. Exhibit 99.1 Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D. NEW YORK, May 30, 2023 –– Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the appointment of Alka Batycky, Ph.D. to its Board of Directors and Audit Committee. “Dr. Batycky is an ac |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2023 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 30, 2023 |
Exhibit 3.1 LANDOS BIOPHARMA, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Landos Biopharma, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), does hereby certify as follows: FIRST: The name of the Company is Landos Biopharma, Inc. SECOND: The Company was originally formed as a corporation organized under the jurisdiction of the State of |
|
| May 25, 2023 |
Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LANDOS BIOPHARMA, INC. Landos Biopharma, Inc. (the “Company”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: First: The name of this corporation is Landos Biopharma, Inc., and the date on which the Ce |
|
| May 25, 2023 |
Landos Biopharma Announces 1-for-10 Reverse Stock Split Exhibit 99.1 Landos Biopharma Announces 1-for-10 Reverse Stock Split NEW YORK, May 25, 2023 –– Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10, to be effective as of 5:00 |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 Landos Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-39971 (Commission File Number) 8 |
|
| May 12, 2023 |
Severance Agreement by and between the Company and Fabio Cataldi, effective as of September 5, 2022. Exhibit 10.1 SEVERANCE AGREEMENT This Severance Agreement (the “Agreement”) is entered into effective September 5, 2022 (the “Effective Date”), by and between Landos Biopharma, Inc. (the “Company”), and Fabio Cataldi (the “Executive”). Whereas, the Company considers it important to foster the continuous employment of its key management personnel; and Whereas, the Company desires to provide the Exe |
|
| May 12, 2023 |
May 2023 Clinical stage biopharmaceutical company focused on developing first-in-class, oral therapeutics for autoimmune disease Corporate Overview Exhibit 99. |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 12, 2023 |
Exhibit 99.1 Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated NEXUS Top-line Results Planned for Q4 2024 Sufficient Cash to Fund Planned Operations into First Half of 2025 NEW YORK, May 12, 2023 –– Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39971 Landos Biopharma, Inc. |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 10, 2023 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 30, 2023 |
LABP / Landos Biopharma Inc / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Landos Biopharma, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 515069 102 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-5340 (Name, Address and Telephon |
|
| March 30, 2023 |
LABP / Landos Biopharma Inc / Xontogeny, LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Landos Biopharma, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 515069 102 (CUSIP Number) Christopher Garabedian Xontogeny, LLC 240 Newbury Street, Suite 201 Boston, MA 02116 (857) 891-0017 (Name, Address and Telephone N |
|
| March 23, 2023 |
Exhibit 10.19 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED FIRST AMENDMENT TO LICENSE AND COLLABORATION AGREEMENT THIS FIRST AMENDMENT TO THE LICENSE AND COLLABORATION AGREEMENT (this “Amendment”) is made as of February 28, 2023 (the “Amendment E |
|
| March 23, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Registration Statement on Form S-8 LANDOS BIOPHARMA, INC. |
|
| March 23, 2023 |
Exhibit 10.17 SEVERANCE AGREEMENT This Severance Agreement (the “Agreement”) is entered into effective December 8, 2022 (the “Effective Date”), by and between Landos Biopharma, Inc. (the “Company”), and Patrick Truesdell (the “Employee”). Whereas, the Company considers it important to foster the continuous employment of its key management personnel; and Whereas, the Company desires to provide the |
|
| March 23, 2023 |
Offer Letter by and between the Company and Patrick Truesdell, effective as of May 3, 2022. Exhibit 10.16 April 7th, 2022 Dear Patrick, I am pleased to confirm the offer of employment to you with Landos Biopharma (“Landos”) in the full-time position of Vice President, Controller. You are tentatively scheduled for a start date of May 3rd, 2022. Base Salary The initial annualized base salary for this position will be $300,000.00 which on a semi-monthly basis will be $12,500.00 (less applic |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39971 Landos Biopharma, Inc. |
|
| March 23, 2023 |
Exhibit 99.1 Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 Results On Track to Initiate Phase 2 Proof-of-Concept Trial in Ulcerative Colitis for NX-13 in the Second Quarter of 2023 and Report Topline Results by the Fourth Quarter of 2024 Projected Cash Runway into First Half of 2025 NEW YORK, March 23, 2023 –– Landos Biopharma, Inc. (NASDAQ: LABP), a clini |
|
| March 23, 2023 |
As filed with the Securities and Exchange Commission on March 23, 2023 As filed with the Securities and Exchange Commission on March 23, 2023 Registration Statement No. |
|
| March 23, 2023 |
Offer Letter by and between the Company and Fabio Cataldi, effective as of September 5, 2022. Exhibit 10.15 July 26, 2022 Fabio Cataldi 53 Preston Pl. Beverly, MA 01915 Re: Offer of Employment Dear Fabio, We are pleased to offer you employment with Landos Biopharma, Inc. (the “Company”), beginning on September 5, 2022. Position Your initial position will be Executive Vice President & Chief Medical Officer, performing such duties as are normally associated with this position and such duties |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 28, 2023 |
Corporate Overview February 28, 2023 Clinical stage biopharmaceutical company focused on the development of first-in-class therapeutics for patients with autoimmune disease. |
|
| February 28, 2023 |
Exhibit 99.2 Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos’ Founder Transaction Solidifies Company’s Near-Term Strategic Focus on Advancing Clinical Development of NX-13 Company Remains On-Track to Initiate the NX-13 Phase 2 Proof-of-Concept Trial in Ulcerative Colitis in the Second Quarter of 2023 NEW YORK, February 28, 2023 – Landos |
|
| February 28, 2023 |
Exhibit 99.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED ASSET PURCHASE AND REDEMPTION AGREEMENT This Asset Purchase and Redemption Agreement (this “Agreement”) dated as of February 28, 2023 between Landos Biopharma, Inc. (“Landos” or “Seller”), |
|
| February 14, 2023 |
LABP / Landos Biopharma Inc / Bassaganya-Riera Josep Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Landos Biopharma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 515069102 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| January 13, 2023 |
Exhibit 10.1 AMENDMENT NO. 1 TO THE AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENT This AMENDMENT NO. 1 TO THE AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENT (this “Amendment”) is made and entered into as of January 10, 2023 by and among Landos Biopharma, Inc., a Delaware corporation (the “Company”) and the Investors listed on the signature pages hereto, and amends that certain Amended and Res |
|
| January 13, 2023 |
LABP / Landos Biopharma Inc / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A 1 d361670dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Landos Biopharma, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 515069 102 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-53 |
|
| January 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 05, 2023 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 5, 2023 |
Corporate Overview January 5, 2023 Corporate Overview January 5, 2023 This presentation contains forward-looking statements that involve substantial risks and uncertainties. |
|
| January 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 04, 2023 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 5, 2023 |
EX-4.1 2 labp-ex41.htm EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PU |
|
| January 5, 2023 |
Exhibit 99.1 Landos Biopharma Provides Comprehensive Update on Clinical Development Plans Advancing NX-13 Clinical Development for Treatment of Ulcerative Colitis On Track to Initiate Phase 2 Proof-of-Concept Trial for NX-13 in the Second Quarter of 2023 and Report Topline Data by the Fourth Quarter of 2024 Broader, Novel Pipeline Poised for Partnering and Continued Development in the Future; Sign |
|
| January 5, 2023 |
Landos Biopharma Announces $16.7 Million Private Placement Financing Exhibit 99.1 Landos Biopharma Announces $16.7 Million Private Placement Financing NEW YORK, January 5, 2023 ? Landos Biopharma, Inc. (NASDAQ: LABP) (?Landos? or the ?Company?), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced a $16.7 million private placement financing from the sale of pre-funded warrants to purchase |
|
| January 5, 2023 |
EX-10.1 3 labp-ex101.htm EX-10.1 Exhibit 10.1 SECURITIES Purchase AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of January 4, 2023, by and between Landos Biopharma, Inc., a Delaware corporation (the “Company”), and the Purchasers identified on Schedule 1 attached hereto (together, the “Purchasers”). Capitalized terms used herein but not otherwise defined shall have the m |
|
| December 16, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39971 Landos Biopharma, Inc. |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 10, 2022 |
Exhibit 99.1 Landos Biopharma Reports Third Quarter 2022 Results and Provides Business Update On Track to Complete Comprehensive Review of Clinical Development Plans in the Coming Weeks NEW YORK, November 10, 2022 –– Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced financial res |
|
| November 3, 2022 |
LABP / Landos Biopharma Inc / RTW INVESTMENTS, LP - LANDOS BIOPHARMA, INC. Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 3) Landos Biopharma, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 515069102 (CUSIP Number) Ele |
|
| October 31, 2022 |
LABP / Landos Biopharma Inc / RTW INVESTMENTS, LP - LANDOS BIOPHARMA, INC. Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 2) Landos Biopharma, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 515069102 (CUSIP Number) Ele |
|
| October 6, 2022 |
LABP / Landos Biopharma Inc / RTW INVESTMENTS, LP - LANDOS BIOPHARMA, INC. Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 1) Landos Biopharma, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 515069102 (CUSIP Number) Ele |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Landos Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 11, 2022 |
NX-13 Phase 1b Clinical Trial Data AUGUST 2022 Exhibit 99.2 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, prospects, plans and objectives of management, are for |
|
| August 11, 2022 |
Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?) is entered into effective June 20, 2022 (the ?Effective Date?), by and between Gregory Oakes (the ?Executive?) and Landos Biopharma, Inc. (the ?Company?). The Company desires to employ the Executive and, in connection therewith, to compensate the Executive for Executive?s personal services to the Comp |
|
| August 11, 2022 |
Exhibit 10.1 Revised May 4, 2022 Jyoti Chauhan 42562 Magellan Square Brambleton, VA 20148 Re: Separation Agreement Dear Jyoti: This letter revises the letter sent to you on February 28, 2022, as initially revised on April 25, 2022, and sets forth the substance of the Separation Agreement (the ?Agreement?) which Landos Biopharma, Inc. (the ?Company?) is offering to you. 1. Separation. Your last day |
|
| August 11, 2022 |
Exhibit 99.1 Landos Biopharma Reports Second Quarter 2022 Results and Provides Business Update Positive Top-Line Results From NX-13 Phase 1b Trial in Ulcerative Colitis Demonstrate a Favorable Safety and Tolerability Profile Across Range of Once-Daily Oral Doses, as well as Promising Early Efficacy Signals Phase 2 Proof of Concept Clinical Trial for NX-13 in Ulcerative Colitis Planned On Track to |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39971 Landos Biopharma, Inc. |
|
| August 11, 2022 |
As filed with the Securities and Exchange Commission on August 11, 2022 As filed with the Securities and Exchange Commission on August 11, 2022 Registration No. |
|
| August 11, 2022 |
August 11, 2022 VIA EDGAR Michael Davis U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Landos Biopharma, Inc. Registration Statement on Form S-3 (File No. 333-263836), as amended by Amendment No. 1 Request for Acceleration of Effective Date Acceleration Request Requested Date: Monday, August 15, 2022 Requested Time: 8:00 a.m. E |
|
| August 9, 2022 |
LABP / Landos Biopharma Inc / Xontogeny, LLC - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Landos Biopharma, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 515069 102 (CUSIP Number) Christopher Garabedian Xontogeny, LLC 240 Newbury Street, Suite 201 Boston, MA 02116 (857) 891-0017 (Name, Address and Telephone Number of |
|
| August 9, 2022 |
Exhibit 3 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. |
|
| August 9, 2022 |
LABP / Landos Biopharma Inc / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Landos Biopharma, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 515069 102 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-5340 (Name, Address and Telephon |
|
| August 3, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 Landos Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 3, 2022 |
Exhibit 99.1 Landos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1b Trial NX-13 Demonstrated Favorable Safety and Tolerability Profile Across Range of Once-Daily Doses Results Indicate Promising Early Signals Regarding the Efficacy of NX-13 Phase 2 Proof of Concept Clinical Trial in Ulcerative Colitis Planned NEW YORK, August 3, 2022— Landos Biopharma, Inc. (NASDAQ: LABP), a clinic |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2022 Landos Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 17, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2022 Landos Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 13, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 Landos Biopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2022 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 18, 2022 |
May 18, 2022 VIA EDGAR Michael Davis U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Request to Withdraw Acceleration Request of Landos Biopharma, Inc., (the ?Company?), dated May 16, 2022 for the Registration Statement on Form S-3 (File No. 333-263836) Dear Mr. Davis, On behalf of the Company, I hereby formally request the with |
|
| May 16, 2022 |
CORRESP 1 filename1.htm May 16, 2022 VIA EDGAR Michael Davis Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Landos Biopharma, Inc. Registration Statement on Form S-3; File No. 333-263836 Acceleration Request Requested Date: Wednesday, May 18, 2022 Requested Time: 4:00 p.m. Eastern Time Dear Mr. Davis: In accordance with Rule 461 under |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39971 Landos Biopharma, Inc. |
|
| May 12, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Landos Biopharma Reports First Quarter 2022 Results and Provides Business Update On Track to Complete Review of Clinical Development Plans by Mid-2022 Top-Line Results for NX-13 Phase 1b and LABP-104 Phase 1 Trials Remain On Track for Mid-2022 Plans to Announce Timing of Phase 2b Trial of Omilancor Later this Year NEW YORK, May 12, 2022 ?? Landos Biopharma, Inc. |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 28, 2022 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 28, 2022 |
Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2022 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2022 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 24, 2022 |
Exhibit 99.1 Landos Biopharma Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update Continued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of Omilancor in Ulcerative Colitis Later this Year Completed Enrollment of Phase 1b Trial of NX-13 in Ulcerative Colitis and Phase 1a Trial of LABP-104 in Normal Healthy Volunteers; Top Line |
|
| March 24, 2022 |
Form of Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.4 LANDOS BIOPHARMA, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF LANDOS BIOPHARMA, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between LANDOS BIOPHARMA, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and existing under |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39971 Landos Biopharma, Inc. |
|
| March 24, 2022 |
Exhibit 10.8 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made as of December 17, 2021 (the ?Effective Date?) by and between Landos Biopharma, Inc. (the ?Company?) and Tim M. Mayleben (the ?Executive?). 1. Employment. The Company and the Executive desire that the Executive be employed as the Company?s Chief Executive Officer on an interim basis. The employment relationship |
|
| March 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2022 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 24, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Registration Statement on Form S-8 LANDOS BIOPHARMA, INC. |
|
| March 24, 2022 | ||
| March 24, 2022 | ||
| March 24, 2022 |
As filed with the Securities and Exchange Commission on March 24, 2022 As filed with the Securities and Exchange Commission on March 24, 2022 Registration No. |
|
| March 24, 2022 |
2022 Inducement Plan and Forms of Stock Option Grant Notice and Option Agreements thereunder Exhibit 99.3 LANDOS BIOPHARMA, INC. 2022 INDUCEMENT PLAN 1. Purposes of the Plan. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under NASDAQ Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under NASDAQ IM 5635-1. A person who previously served as an Employee or Director will n |
|
| March 24, 2022 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.6 LANDOS BIOPHARMA, INC. AND [], AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF [] LANDOS BIOPHARMA, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between LANDOS BIOPHARMA, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and |
|
| March 24, 2022 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.5 LANDOS BIOPHARMA, INC. AND [], AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF LANDOS BIOPHARMA, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between LANDOS BIOPHARMA, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and exi |
|
| March 24, 2022 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables Registration Statement on Form S-3 LANDOS BIOPHARMA, INC. |
|
| March 24, 2022 |
Exhibit 10.7 SEPARATION AND RELEASE OF CLAIMS AGREEMENT This Separation and Release of Claims Agreement (the ?Agreement?) is entered into by and between Landos Biopharma, Inc. (the ?Company?) and Josep Bassaganya-Riera (?Executive?) (together, the ?Parties?). WHEREAS, the Company and Executive are parties to the Employment Agreement dated as of January 1, 2020 (the ?Employment Agreement?); WHEREAS |
|
| March 24, 2022 | ||
| March 24, 2022 |
Exhibit 10.9 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made as of December 17, 2021 (the ?Effective Date?) by and between Landos Biopharma, Inc. (the ?Company?) and Patricia Bitar (the ?Executive?). 1. Employment. The Company and the Executive desire that the Executive be employed as the Company?s Chief Financial Officer on an interim basis. The employment relationship b |
|
| March 24, 2022 |
As filed with the Securities and Exchange Commission on March 24, 2022 Table of Contents As filed with the Securities and Exchange Commission on March 24, 2022 Registration No. |
|
| March 24, 2022 |
Form of Indenture, between the Registrant and one or more trustees to be named. Table of Contents Exhibit 4.2 LANDOS BIOPHARMA, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities Table of Contents TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securit |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2022 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| March 10, 2022 |
Landos Biopharma Appoints Roger Adsett to its Board of Directors Exhibit 99.1 FOR IMMEDIATE RELEASE Landos Biopharma Appoints Roger Adsett to its Board of Directors BLACKSBURG, Va., March 10, 2022 ? Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it has appointed Roger Adsett to the Company?s Board of Directors, effective March 8, 2022. |
|
| February 14, 2022 |
LABP / Landos Biopharma Inc / Bassaganya-Riera Josep Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Landos Biopharma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 515069102 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| February 3, 2022 |
LABP / Landos Biopharma Inc / Osage University GP III, LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* LANDOS BIOPHARMA, INC. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 515069 102 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 3, 2022 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. |
|
| January 13, 2022 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2022 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission |
|
| December 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2021 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39971 Landos Biopharma, Inc. |
|
| November 15, 2021 |
Exhibit 99.1 Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update Enhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization Refining Ulcerative Colitis Clinical Development Plans for Omilancor to Generate Additional Phase 2b Data Prior to Initiating Pivotal Phase 3 Program Determining Optimal Enrollment for Phase 2 Cli |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2021 Landos Biopharma, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| November 3, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) November 2, 2021 Landos Biopharma, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 3, 2021 |
Landos Biopharma Announces FDA Clearance of its IND for Exhibit 99.1 Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Rheumatoid Arthritis Phase 1 trial is underway with topline results expected in the first half of 2022 Represents Landos? seventh IND cleared overall and the second IND cleared for LABP-104, a potentially first-in-class therapeutic candidate for systemic lupus erythematosus and rheumatoid arthritis B |
|
| October 28, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) October 28, 2021 Landos Biopharma, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 28, 2021 |
Exhibit 99.1 Landos Biopharma Announces First Subject Dosed in a Phase 1 Study of LABP-104 for Systemic Lupus Erythematosus October 28, 2021 Topline results are expected in the first half of 2022 A whole blood LABP-104 precision medicine signature will be assessed during the trial BLACKSBURG, Va., Oct. 28, 2021 (GLOBE NEWSWIRE) ? Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biophar |
|
| October 12, 2021 |
Phase 1 trial initiation expected before yearend with topline results in 1H 2022 Exhibit 99.1 Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Systemic Lupus Erythematosus October 11, 2021 Phase 1 trial initiation expected before yearend with topline results in 1H 2022 BLACKSBURG, Va., Oct. 11, 2021 (GLOBE NEWSWIRE) ? Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE? Advanced A.I. pl |
|
| October 12, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) October 11, 2021 Landos Biopharma, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 8, 2021 |
Exhibit 99.1 Landos Biopharma Announces Publication in Scientific Reports of Novel Preclinical Findings Demonstrating Omilancor?s Therapeutic Potential in Models of Psoriasis and Further Validating the LANCL2 Mechanism BLACKSBURG, Va., Oct. 06, 2021 ? Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE? Advanced A.I. platform to discover and d |
|
| October 8, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) October 6, 2021 Landos Biopharma, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission f |
|
| September 22, 2021 |
Exhibit 99.1 Landos Biopharma to Collaborate on a Phase 2 Study of Omilancor in Crohn?s Disease with the Icahn School of Medicine at Mount Sinai Second Phase 2 trial of omilancor in Crohn?s disease (CD), expected to initiate in 2021 Awarded a $3 million NIH R01 grant from the U.S. National Institute of Diabetes and Digestive and Kidney Diseases to fund this study BLACKSBURG, Va., September 20, 202 |
|
| September 22, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) September 20, 2021 Landos Biopharma, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| September 17, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) September 15, 2021 Landos Biopharma, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| September 17, 2021 |
EX-99.1 2 d202757dex991.htm EX-99.1 Exhibit 99.1 Landos Biopharma to Present Results of LABP-104 in Lupus at the American College of Rheumatology Convergence 2021 Oral treatment with LABP-104 in preclinical models of Systemic Lupus Erythematosus (SLE) resulted in enhanced Treg function, decreased kidney inflammation and reduced interferon gamma signaling; Phase 1 clinical trial anticipated to begi |
|
| August 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2021 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 26, 2021 |
Exhibit 99.1 Landos Biopharma Announces Research Collaboration into the NLRX1 Pathway in Multiple Sclerosis with Johns Hopkins University School of Medicine BLACKSBURG, Va., August 26, 2021 ? Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE? Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, tod |
|
| August 26, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2021 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2021 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| August 2, 2021 |
EX-99.1 2 d209827dex991.htm EX-99.1 Exhibit 99.1 Landos Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Updates Following the recent positive End-of-Phase 2 meeting with the FDA, Landos initiated global pivotal Phase 3 clinical trial site feasibility studies of omilancor in ulcerative colitis (UC) Initiated enrollment of Phase 2 trial of omilancor in Crohn’s Disease ( |
|
| July 29, 2021 |
Exhibit 1.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED LICENSE AND COLLABORATION AGREEMENT THIS LICENSE AND COLLABORATION AGREEMENT (this ?Agreement?), entered into as of May 14, 2021 (the ?Effective Date?), is entered into by and between LianB |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39971 Landos Biopharma, Inc. |
|
| July 22, 2021 |
Exhibit 99.1 Landos Biopharma?s Phase 2 Data of Omilancor in Ulcerative Colitis Accepted for Oral Presentation at the United European Gastroenterology Week 2021 Omilancor shows efficacy and tolerability as a potential once-daily, oral, gut-restricted therapy for mild-to-moderate UC patients Following the recent positive End-of-Phase 2 meeting with the FDA, Landos initiated clinical trial site feas |
|
| July 22, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2021 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 14, 2021 |
Landos Biopharma Announces Positive Outcome of Exhibit 99.1 Landos Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Omilancor in Mild-to-Moderate Active Ulcerative Colitis (UC) Patients The FDA clears the path to initiate the PACIFY I and II global registration studies in Mild-to-Moderate Active UC patients representing the potential for a broad product label for Omilancor BLACKSBURG, Va., June 14, 2021 (GLOBE NE |
|
| June 14, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2021 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 19, 2021 |
Landos Biopharma Announces the Appointment of Tim M. Mayleben to its Board of Directors Exhibit 99.1 Landos Biopharma Announces the Appointment of Tim M. Mayleben to its Board of Directors BLACKSBURG, Va., May 19 2021 ? Landos Biopharma, Inc (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the appointment of Tim M. Mayleben to its Board of Directors. Mr. Mayleben |
|
| May 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 17, 2021 |
Exhibit 99.2 Landos Biopharma and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Omilancor and NX-13 in Greater China and Select Asian Markets Blacksburg, Va., & Shanghai, China and Princeton, N.J., May 17, 2021 - Landos Biopharma, Inc (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2021 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39971 Landos Biopharma, Inc. |
|
| May 17, 2021 |
S-8 1 d137526ds8.htm S-8 As filed with the Securities and Exchange Commission on May 17, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Landos Biopharma, Inc. (Exact name of Registrant as specified in its charter) Delaware 81-5085535 (State or other jurisdiction of incorporation or |
|
| May 17, 2021 |
Exhibit 99.1 Landos Biopharma Reports First Quarter 2021 Financial Results and Provides Business Updates Completed initial public offering of common stock, raising approximately $100 million in gross proceeds Following positive Phase 2 results of omilancor in ulcerative colitis, including statistically significant immunological and biomarker results, end-of-Phase 2 Meeting with FDA planned for Q2 |
|
| May 7, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 7, 2021 |
EX-99.1 2 d146305dex991.htm EX-99.1 Exhibit 99.1 Landos Biopharma Announces First Patient Dosed in a Phase 2 Study of Omilancor for Moderate-to-Severe Crohn’s Disease Company’s second omilancor program entering a Phase 2 study with plans to pursue at least five autoimmune indications Topline results are expected in the second quarter of 2022 BLACKSBURG, VA., May 6, 2021 – Landos Biopharma (NASDAQ: |
|
| April 29, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2021 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 29, 2021 |
Exhibit 99.1 Landos Biopharma Announces First Patient Dosed in a Phase 1b Study of NX-13 for Ulcerative Colitis Landos? second first-in-class product candidate designed to provide a safer and more convenient treatment for ulcerative colitis patients Topline results are expected in the first quarter of 2022 BLACKSBURG, Va., April 29, 2021- Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharma |
|
| April 13, 2021 |
Landos Biopharma Announces the Appointment of Tiago Girão to its Board of Directors EX-99.1 2 d127292dex991.htm EX-99.1 EXHIBIT 99.1 Landos Biopharma Announces the Appointment of Tiago Girão to its Board of Directors BLACKSBURG, Va., April 13, 2021 — Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the appointment of Tiago Girão to its Board o |
|
| April 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2021 Landos Biopharma, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 6, 2021 |
SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Landos Biopharma, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 515069 102 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-5340 (Name, Address and Telephon |
|
| March 31, 2021 |
Exhibit 10.6 LANDOS BIOPHARMA, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY APPROVED BY THE BOARD OF DIRECTORS ON March 30, 2021 Each member of the Board of Directors (the ?Board?) of Landos Biopharma, Inc. (the ?Company?) who is a non-employee director of the Company (each such member, a ?Non-Employee Director?) will receive the compensation described in this Non-Employee Director Compensation |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39971 Landos Biopharma, Inc. |
|
| March 31, 2021 |
Exhibit 4.2 DESCRIPTION OF LANDOS BIOPHARMA, INC. COMMON STOCK The following description of the common stock of Landos Biopharma, Inc., or the Company, and certain provisions of the Company?s amended and restated certificate of incorporation, or the restated certificate, and amended and restated bylaws, or restated bylaws, are summaries. These summaries are qualified in the entirety by reference t |
|
| February 18, 2021 |
EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Dated: February 18, 2021 PE |
|
| February 18, 2021 |
SC 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment )* Landos Biopharma, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 515069 102 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-5340 (Name, Address and Telephone Number |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. N/A)* LANDOS BIOPHARMA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 515069102 (CUSIP Number) RTW Investments, LP Attn: Roderick Wong 40 10th Avenue, Floor 7, New York, New York 10014 (Name, Address and Telephone Number of Person Authori |
|
| February 16, 2021 |
Exhibit 2 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13D under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock of Landos Biopharma, Inc. |
|
| February 8, 2021 |
EX-3.1 Exhibit 3.1 LANDOS BIOPHARMA, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Landos Biopharma, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), does hereby certify as follows: FIRST: The name of the Company is Landos Biopharma, Inc. SECOND: The Company was originally formed as a corporation organized under the jurisdiction of the St |
|
| February 8, 2021 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2021 Landos Biopharma, Inc. (Exact name of registrant as specified in its Charter) Delaware 001-39971 81-5085535 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 4, 2021 |
424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-252083 Prospectus 6,250,000 shares Common stock This is an initial public offering of shares of common stock Landos Biopharma, Inc. We are offering 6,250,000 shares of our common stock. The initial public offering price is $16.00 per share. Prior to this offering, there has been no public market for our common stock. Our |
|
| February 1, 2021 |
VIA EDGAR February 1, 2021 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| February 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Landos Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 81-5085535 (State of incorporation or organization) (I.R.S. Employer Identification No.) 1800 Kraft Drive, Sui |
|
| February 1, 2021 |
Exhibit 3.1 Execution Version AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LANDOS BIOPHARMA INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Landos Biopharma Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTI |
|
| February 1, 2021 |
LANDOS BIOPHARMA, INC. 1800 Kraft Drive, Suite 216 Blacksburg, VA 24060 Februaruy 1, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jenn Do Kevin Kuhar Christopher Edwards Alan Campbell RE: Landos Biopharma, Inc. Registration Statement on Form S-1 File No. 333-252083 Acceleration Request Requested Date |
|
| February 1, 2021 |
Eric Blanchard +1 212 479 6565 [email protected] February 1, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Jenn Do Kevin Kuhar Christopher Edwards Alan Campbell Re: Landos Biopharma, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed January 28, 2021 File No. 333-252083 Ladies and Gentlemen: On behalf of |
|
| February 1, 2021 |
S-1/A Table of Contents As filed with the Securities and Exchange Commission on February 1, 2021 Registration No. |
|
| January 28, 2021 |
EX-10.3 Exhibit 10.3 LANDOS BIOPHARMA, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is dated as of , 2021, and is between Landos Biopharma, Inc., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”). RECITALS A. Indemnitee’s service to the Company substantially benefits the Company. B. Individuals are reluctant to serve as directors or officers of corp |
|
| January 28, 2021 |
Form of Underwriting Agreement EX-1.1 Exhibit 1.1 UNDERWRITING AGREEMENT Landos Biopharma, Inc. Shares of Common Stock Underwriting Agreement [ 🌑 ], 2021 J.P. MORGAN SECURITIES LLC JEFFERIES LLC SVB LEERINK LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o SVB |
|
| January 28, 2021 |
EX-10.2 Exhibit 10.2 Privileged and Confidential FINAL LANDOS BIOPHARMA, INC. 2019 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of the Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors, and Consultants and to promote the success of the business of the Company. 2. Definitions. The following definitions shall apply as |
|
| January 28, 2021 |
S-1/A Table of Contents As filed with the Securities and Exchange Commission on January 28, 2021 Registration No. |
|
| January 28, 2021 |
CORRESP 1 filename1.htm Eric Blanchard +1 212 479 6565 [email protected] January 28, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Jenn Do Kevin Kuhar Christopher Edwards Alan Campbell Re: Landos Biopharma, Inc. Registration Statement on Form S-1 Filed January 13, 2021 File No. 333-252083 Ladies and Gentlemen: On beha |
|
| January 28, 2021 |
2021 Employee Stock Purchase Plan EX-10.5 Exhibit 10.5 LANDOS BIOPHARMA, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: [], 2021 APPROVED BY THE STOCKHOLDERS: [], 2021 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant |
|
| January 28, 2021 |
EX-3.4 Exhibit 3.4 LANDOS BIOPHARMA, INC. AMENDED AND RESTATED BYLAWS ARTICLE I OFFICES Section 1. Registered Office. The registered office shall be established and maintained at the office of Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, in the County of New Castle, in the State of Delaware, 19801 and said corporation, or other such person or entity as the Board of Dire |
|
| January 28, 2021 |
EX-3.3 Exhibit 3.3 LANDOS BIOPHARMA, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Landos Biopharma, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), does hereby certify as follows: FIRST: The name of the Company is Landos Biopharma, Inc. SECOND: The Company was originally formed as a corporation organized under the jurisdiction of the St |
|
| January 13, 2021 |
CORRESP 1 filename1.htm Eric Blanchard +1 212 479 6565 [email protected] January 13, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Jenn Do Kevin Kuhar Christopher Edwards Alan Campbell Re: Landos Biopharma, Inc. Amendment No. 2 to Draft Registration Statement on Form S-1 Submitted November 30, 2020 CIK No. 0001785345 |
|
| January 13, 2021 |
EX-10.1 Exhibit 10.1 Execution Version AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENT (this “Agreement”), is made as of the 9th day of August, 2019, by and among Landos Biopharma, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” |
|
| January 13, 2021 |
Bylaws of the Registrant (currently in effect) EX-3.2 Exhibit 3.2 LANDOS BIOPHARMA, INC. BYLAWS (the “Corporation”) These Bylaws have been approved by the Board of Directors of the Corporation. ARTICLE I Stockholders 1. Annual Meeting. The annual meeting of stockholders shall be held each year at the place, date and time determined by the Board of Directors or the President. The purposes for which the annual meeting is to be held, in addition |
|
| January 13, 2021 |
Amended and Restated Certificate of Incorporation of the Registrant (currently in effect) EX-3.1 Exhibit 3.1 Execution Version AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LANDOS BIOPHARMA INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Landos Biopharma Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREB |
|
| January 13, 2021 |
Power of Attorney (included on signature page) S-1 Table of Contents As filed with the Securities and Exchange Commission on January 13, 2021 Registration No. |
|
| January 13, 2021 |
EX-10.4 Exhibit 10.4 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), made effective as of January 1, 2020 (“Effective Date”), by and between Landos Biopharma, Inc. (the “Company”), and Dr. Josep Bassaganya-Riera (“Employee”) provides: Employee founded the Company on January 6th of 2017 and has been serving as the Chairman of the Board, President, and Chief Executive Officer (“CEO |
|
| December 1, 2020 |
Exhibit 10.4 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), made effective as of January 1, 2020 (?Effective Date?), by and between Landos Biopharma, Inc. (the ?Company?), and Dr. Josep Bassaganya-Riera (?Employee?) provides: Employee founded the Company on January 6th of 2017 and has been serving as the Chairman of the Board, President, and Chief Executive Officer (?CEO?) of th |
|
| December 1, 2020 |
AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENT Exhibit 10.1 Execution Version AMENDED AND RESTATED INVESTOR?S RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTOR?S RIGHTS AGREEMENT (this ?Agreement?), is made as of the 9th day of August, 2019, by and among Landos Biopharma, Inc., a Delaware corporation (the ?Company?), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an ?Investor?. RECITA |
|
| December 1, 2020 |
LANDOS BIOPHARMA, INC. 2019 EQUITY INCENTIVE PLAN EX-10.2 5 filename5.htm Exhibit 10.2 Privileged and Confidential FINAL LANDOS BIOPHARMA, INC. 2019 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of the Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors, and Consultants and to promote the success of the business of the Company. 2. Definitions. The following definition |
|
| December 1, 2020 |
Table of Contents As submitted to the Securities and Exchange Commission confidentially on November 30, 2020 as Amendment No. |
|
| December 1, 2020 |
Exhibit 3.2 LANDOS BIOPHARMA, INC. BYLAWS (the ?Corporation?) These Bylaws have been approved by the Board of Directors of the Corporation. ARTICLE I Stockholders 1. Annual Meeting. The annual meeting of stockholders shall be held each year at the place, date and time determined by the Board of Directors or the President. The purposes for which the annual meeting is to be held, in addition to thos |
|
| December 1, 2020 |
Exhibit 3.1 Execution Version AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LANDOS BIOPHARMA INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Landos Biopharma Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTI |
|
| November 30, 2020 |
Eric Blanchard +1 212 479 6565 [email protected] November 30, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Jenn Do Kevin Kuhar Christopher Edwards Alan Campbell Re: Landos Biopharma, Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted September 1, 2020 CIK No. 0001785345 Ladies and Gentlemen: O |
|
| September 1, 2020 |
Eric Blanchard +1 212 479 6565 [email protected] September 1, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Jenn Do Kevin Kuhar Christopher Edwards Alan Campbell Re: Landos Biopharma, Inc. Draft Registration Statement on Form F-1 Submitted July 24, 2020 CIK No. 0001785345 Ladies and Gentlemen: On behalf of Landos Biop |
|
| September 1, 2020 |
Table of Contents As submitted to the Securities and Exchange Commission confidentially on September 1, 2020 as Amendment No. |
|
| July 24, 2020 |
As submitted to the Securities and Exchange Commission confidentially on July 24, 2020 Table of Contents As submitted to the Securities and Exchange Commission confidentially on July 24, 2020 Registration No. |
